These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 8832011

  • 21. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
    Horn B, Reiss U, Matthay K, McMillan A, Cowan M.
    Bone Marrow Transplant; 2002 Mar; 29(5):409-15. PubMed ID: 11919731
    [Abstract] [Full Text] [Related]

  • 22. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.
    Brugieres L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C, Kalifa C, Flamant F, Lemerle J.
    Bone Marrow Transplant; 1988 Jan; 3(1):53-8. PubMed ID: 3048471
    [Abstract] [Full Text] [Related]

  • 23. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringdén O, Eber S, Seger R, Ljungman P.
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [Abstract] [Full Text] [Related]

  • 24. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH, Lee KH, Choi SJ, Min YJ, Kim JG, Kim S, Lee JS, Kim SH, Park CJ, Chi HS, Kim WK.
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [Abstract] [Full Text] [Related]

  • 25. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 26. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
    Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, Ezzone SA, Scholl MD, Belt PS, Young DC, Avalos BR.
    Bone Marrow Transplant; 2000 Nov; 26(10):1037-43. PubMed ID: 11108300
    [Abstract] [Full Text] [Related]

  • 27. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D.
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [Abstract] [Full Text] [Related]

  • 28. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M, Van Camp B.
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [Abstract] [Full Text] [Related]

  • 29. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
    Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Penza SL.
    Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
    [Abstract] [Full Text] [Related]

  • 30. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [Abstract] [Full Text] [Related]

  • 33. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ.
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 37. Ursodiol to prevent hepatic venoocclusive disease.
    Comcowich SA, Spitzer TR, Tsunoda SM.
    Ann Pharmacother; 1997 Oct; 31(10):1249-52. PubMed ID: 9337452
    [Abstract] [Full Text] [Related]

  • 38. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
    Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R.
    Blood; 2008 Dec 01; 112(12):4425-31. PubMed ID: 18776081
    [Abstract] [Full Text] [Related]

  • 39. Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
    Atkinson K, Biggs J, Noble G, Ashby M, Concannon A, Dodds A.
    Bone Marrow Transplant; 1987 Dec 01; 2(4):385-94. PubMed ID: 3332186
    [Abstract] [Full Text] [Related]

  • 40. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation.
    Blostein MD, Paltiel OB, Thibault A, Rybka WB.
    Bone Marrow Transplant; 1992 Nov 01; 10(5):439-43. PubMed ID: 1464007
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.